Saveria Mazzara
Overview
Explore the profile of Saveria Mazzara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
545
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Talarico G, Franceschini A, Raveane A, Falvo P, Mazzara S, Melle F, et al.
Discov Oncol
. 2024 Dec;
15(1):764.
PMID: 39692827
The clinical presentation of T-cell large granular lymphocytic leukemia (T-LGLL) is extremely variable: 30% of patients have neutropenia with no associated symptoms, others present with bacterial infections and sepsis may...
2.
Travaini L, Botta F, Derenzini E, Lo Presti G, Ferrari M, Airo Farulla L, et al.
Hematol Oncol
. 2023 May;
41(4):674-682.
PMID: 37209024
To evaluate the association between radiomic features (RFs) extracted from F-FDG PET/CT ( F-FDG-PET) with progression-free survival (PFS) and overall survival (OS) in diffuse large-B-cell lymphoma (DLBCL) patients eligible to...
3.
Sapienza M, Chiaretti S, Cardinali D, Mazzara S, Chiarle R, Foa R, et al.
Hematol Oncol
. 2023 Apr;
41(4):789-791.
PMID: 37016899
No abstract available.
4.
Mazzara S, Travaini L, Botta F, Granata C, Motta G, Melle F, et al.
Blood Adv
. 2023 Feb;
7(4):630-643.
PMID: 36806558
Emerging evidence indicates that chemoresistance is closely related to altered metabolism in cancer. Here, we hypothesized that distinct metabolic gene expression profiling (GEP) signatures might be correlated with outcome and...
5.
Del Corvo M, Mazzara S, Pileri S
Bioinform Adv
. 2023 Jan;
2(1):vbac070.
PMID: 36699358
Motivation: Accurate classification of somatic variants in a tumor sample is often accomplished by utilizing a paired normal tissue sample from the same patient to enable the separation of private...
6.
Torrisi R, Vaira V, Giordano L, Destro A, Basilico V, Mazzara S, et al.
Sci Rep
. 2022 Jul;
12(1):12789.
PMID: 35896637
We retrospectively investigated in women treated with fulvestrant for HR+/HER2 negative advanced breast cancer clinical, pathological and molecular features associated with long-term benefit from treatment defined as being progression-free at...
7.
Vegliante M, Mazzara S, Zaccaria G, De Summa S, Esposito F, Melle F, et al.
Hematol Oncol
. 2022 Jul;
40(5):864-875.
PMID: 35850118
The role of macrophages (Mo) and their prognostic impact in diffuse large B-cell lymphomas (DLBCL) remain controversial. By regulating the lipid metabolism, Liver-X-Receptors (LXRs) control Mo polarization/inflammatory response, and their...
8.
Tabanelli V, Melle F, Motta G, Mazzara S, Fabbri M, Agostinelli C, et al.
Blood Adv
. 2022 Jun;
6(15):4634-4644.
PMID: 35767735
T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare and aggressive variant of diffuse large B-cell lymphoma (DLBCL) that usually affects young to middle-aged patients, with disseminated disease at presentation. The...
9.
LImperio V, Morello G, Vegliante M, Cancila V, Bertolazzi G, Mazzara S, et al.
Eur J Immunol
. 2022 May;
52(8):1350-1361.
PMID: 35554927
The GC reaction results in the selection of B cells acquiring effector Ig secreting ability by progressing toward plasmablastic differentiation. This transition is associated with exclusion from the GC microenvironment....
10.
Carpen L, Falvo P, Orecchioni S, Mitola G, Hillje R, Mazzara S, et al.
Cell Death Discov
. 2022 Mar;
8(1):106.
PMID: 35260564
Breast cancer (BC) constitutes a major health problem worldwide, making it the most common malignancy in women. Current treatment options for BC depend primarily on histological type, molecular markers, clinical...